Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 257.

https://doi.org/10.1182/blood-2025-257

Published: 2025

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 2293.

https://doi.org/10.1182/blood-2025-2293

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan, Tengteng Yu, Xiong Wenjie, Ying Yu, Qi Wang, Shuaishuai Zhang, Hesong Zou, Shuhui Deng, Yan Xu, Dehui Zou, Liang Huang, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2025-5379

Published: 2025

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

Jingyu Xu, Qirui Bai, Yuntong Liu, Wenqiang Yan, Shuaishuai Zhang, Wenyang Huang, Chenxing Du, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2025-4067

Published: 2025

Journal Articles

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Tingyu Wang, Yuting Yan, Ying Yu, Xiong Wenjie, Rui Lv, Tengteng Yu, Wei LIU, Yan Xu, Weiwei Sui, Wenyang Huang, Shuaishuai Zhang, Qi Wang, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2025-2124

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Yuntong Liu, Weiwei Sui, Rui Lyu, Chenxing DU, Shuaishuai Zhang, Tengteng Yu, Jingyu Xu, Wenqiang Yan, Yuting Yan, Wei Liu, Yi Wang, Qi Wang, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2024-200117

Published: 2024

Journal Articles

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan, Chenxing DU, Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2024-199913

Published: 2024

Journal Articles

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Yan Xu, Gang An, Wei LIU, Qi Wang, Yi Wang, Shuaishuai Zhang, Wenjie Xiong, Tengteng Yu, Mingwei Fu, Shuhua Yi, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 7228.

https://doi.org/10.1182/blood-2024-209328

Published: 2024

Journal Articles

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Jingyu Xu, Shuaishuai Zhang, Wenqiang Yan, Yuntong Liu, Rui Lyu, Chenxing DU, Weiwei Sui, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2024-200847

Published: 2024

Journal Articles

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Chenxing Du, Shuaishuai Zhang, Lugui Qiu, Gang An, Wenqiang Yan, Jian Cui, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou

Blood (2024) 144 (Supplement 1): 7068.

https://doi.org/10.1182/blood-2024-207775

Published: 2024

Journal Articles

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Wenqiang Yan, Lihui Shi, Jingyu Xu, Lingna Li, Jian Cui, Chenxing DU, Tengteng Yu, Shuaishuai Zhang, Rui Lv, Weiwei Sui, Shuhui Deng, Yan Xu, Dehui Zou, Lu-Gui Qiu, Mu Hao, Gang An

Blood (2024) 144 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2024-199452

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

PHF19 Promotes Drug Resistance through EZH2 Inactivation in Multiple Myeloma

Tengteng Yu, MD, Lanting Liu, Shuaishuai Zhang, MD, Mu Hao, MD,PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 4495.

https://doi.org/10.1182/blood.V128.22.4495.4495

Published: 2016

Journal Articles

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma

Mridul Roy, Long Liang, Xiaojuan Xiao, Yuanliang Peng, Yuhao Luo, Weihua Zhou, Ji Zhang, Lugui Qiu, Shuaishuai Zhang, Feng Liu, Xiuli An, MD PhD, Mao Ye, Wen Zhou, PhD, Jing Liu, PhD

Blood (2016) 128 (22): 3265.

https://doi.org/10.1182/blood.V128.22.3265.3265

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

PHF19 Promotes Drug Resistance through EZH2 Inactivation in Multiple Myeloma

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only